Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Operating Expenses (2016 - 2025)

Enanta Pharmaceuticals filings provide 14 years of Operating Expenses readings, the most recent being $29.9 million for Q4 2025.

  • On a quarterly basis, Operating Expenses fell 26.26% to $29.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $140.0 million, a 20.85% decrease, with the full-year FY2025 number at $150.7 million, down 20.42% from a year prior.
  • Operating Expenses hit $29.9 million in Q4 2025 for Enanta Pharmaceuticals, down from $33.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $58.1 million in Q4 2021 to a low of $29.9 million in Q4 2025.
  • Median Operating Expenses over the past 5 years was $49.9 million (2021), compared with a mean of $47.9 million.
  • Biggest five-year swings in Operating Expenses: surged 33.65% in 2021 and later decreased 26.26% in 2025.
  • Enanta Pharmaceuticals' Operating Expenses stood at $58.1 million in 2021, then fell by 7.68% to $53.6 million in 2022, then decreased by 1.32% to $52.9 million in 2023, then fell by 23.42% to $40.5 million in 2024, then fell by 26.26% to $29.9 million in 2025.
  • The last three reported values for Operating Expenses were $29.9 million (Q4 2025), $33.5 million (Q3 2025), and $37.2 million (Q2 2025) per Business Quant data.